Drug therapy for peripheral vestibular vertigo
https://doi.org/10.14412/2074-2711-2017-1-106-110
Abstract
The choice of effective treatments for vestibular vertigo is one of the important problems, by taking into account the high prevalence of peripheral vestibular diseases. Different drugs, such as vestibular suppressants for the relief of acute vertigo attacks and vestibular compensation stimulants for rehabilitation treatment, are used to treat vestibular vertigo. Drug therapy in combination with vestibular exercises is effective in patients with vestibular neuronitis, Meniere's disease, so is that with therapeutic maneuvers in patients with benign paroxysmal positional vertigo. The high therapeutic efficacy and safety of betahistines permit their extensive use for the treatment of various vestibular disorders.
About the Authors
L. M. Antonenko
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
A.Ya. Kozhevnikov Clinic of Nervous System Diseases, Department of Nervous System Diseases and Neurosurgery, Faculty of General Medicine
V. A. Parfenov
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia
Russian Federation
A.Ya. Kozhevnikov Clinic of Nervous System Diseases, Department of Nervous System Diseases and Neurosurgery, Faculty of General Medicine
Russian Federation
A.Ya. Kozhevnikov Clinic of Nervous System Diseases, Department of Nervous System Diseases and Neurosurgery, Faculty of General Medicine
References
1. Murdin L, Schilder AG. Epidemiology of balance symptoms and disorders in the community: a systematic review. Otol Neurotol. 2015 Mar;36(3):387-92. doi: 10.1097/MAO.0000000000000691.
2. Neuhauser HK, Radtke A, von Brevern M, et al. Burden of dizziness and vertigo in the community. Arch Intern Med. 2008 Oct 27; 168(19):2118-24. doi: 10.1001/archinte.168.19.2118.
3. Yardley L, Owen N, Nazareth I, Luxon L. Prevalence and presentation of dizziness in a general practice community sample of working age people. Br J Gen Pract. 1998 Apr;48(429):1131-5.
4. Парфенов ВА, Замерград МВ, Мельников ОА. Головокружение: диагностика и лечение, распространенные диагностические ошибки. Москва: МИА; 2009. 152 с. [Parfenov VA, Zamergrad MV, Mel'nikov OA. Golovokruzhenie: diagnostika i lechenie, rasprostranennye diagnosticheskie oshibki [Dizziness: diagnosis and treatment, common diagnostic errors]. Moscow: MIA; 2009. 152 p.]
5. Neuhauser HK, von Brevern M, Radtke A, et al. Epidemiology of vestibular vertigo: a neurotologic survey of the general population. Neurology. 2005 Sep 27;65(6):898-904.
6. Thompson TL, Amedee R. Vertigo: a review of common peripheral and central vestibular disorders. Ochsner J. 2009 Spring;9(1):20-6.
7. Strupp M, Hupert D, Frenzel C, et al. Longterm prophylactic treatment of attacks of vertigo in Meniеre's disease-comparison of a high with a low dosage of betahistine in an open trial. Acta Otolaryngol. 2008 May;128(5):520-4. doi: 10.1080/00016480701724912.
8. Lacour M, Sterkers O. Histamine and betahistine in the treatment of vertigo: elucidation of mechanisms of action. CNS Drugs. 2001;15(11):853-70.
9. Oosterveld WJ. Betahistine dihydrochloride in the treatment of vertigo of peripheral vestibular origin. A double-blind placebo-controlled study. J Laryngol Otol. 1984 Jan;98(1):37-41.
10. Guneri EA, Kustutan O. The effects of betahistine in addition to epley maneuver in posterior canal benign paroxysmal positional vertigo. Otolaryngol Head Neck Surg. 2012 Jan;146(1):104-8. doi: 10.1177/0194599811419093. Epub 2011 Aug 18.
11. Conraux C. Les sensations vertgigineuses chroniques: Esai comparatif Serc 8 MG versus placebo en double aveugle randomise, multicentrique chez des patients souffrant de sensations vertigineuses chroniques. Impact Medecin. 1988;260:63-65.
12. Legent F, Calais C, Cellier D. Vertiges paroxystiques iteratifs et Serc. Etude clinique controlee. Concours Med. 1988;110(29):2539-43
13. Mira E, Guidetti G, Ghilardi L, et al. Betahistine dihydrochloride in the treatment of peripheral vestibular vertigo. Eur Arch Otorhinolaryngol. 2003 Feb;260(2):73-7. Epub 2002 Sep 11.
14. Petrova D, Sachansca T, Datcov E. Investigation of Betaserc in auditory and vestibular disturbances. Int Tinnitus J. 2004;10(2):177-82.
15. Gananca MM, Caovilla HH, Gananca FF. Comparable efficacy and tolerability between twice daily and three times daily betahistine for Mеniеre's disease. Acta Otolaryngol. 2009 May;129(5):487-92. doi: 10.1080/00016480802273082.
16. Benecke H, Perez-Garrigues H, Bin Sidek D, et al.; OSVaLD investigators. Effects of betahistine on patient-reported outcomes in routine practice in patients with vestibular vertigo and appraisal of tolerability: experience in the OSVaLD study. Int Tinnitus J. 2010;16(1):14-24.
17. Brandt T, Dieterich M. Vertigo and dizziness: common complains. London: Springer; 2004. 503 p.
18. Haguenauer JP. Clinical study of piracetam in the treatment of vertigo. Les Cahiers d' O. R.L. 1986; 21(6):460-6
19. Rosenhall U, Deberdt W, Friberg U, et al. Piracetam in patients with chronic vertigo. Clin Drug Invest. 1996;11(5): 251-60.
20. Staab JP. Chronic dizziness: the interface between psychiatry and neuro-otology. Curr Opin Neurol. 2006 Feb;19(1):41-8.
21. Hamann KF. Special ginkgo extract in casesof vertigo: a systematic review of randomised, double-blind, placebo controlled clinical examinations. HNO. 2007 Apr;55(4):258-63.
22. Claussen CF, Kirtane MV. Randomisierte doppelblindstudie zur wirkung von extractum Ginkgo biloba bei Schwindel und Gangunsicherheit des alteren Menschen. In: Claussen CF, editor. Presyvertigo, Presbyataxie, Presbytinnitus. Berlin: Springer; 1985.
23. James AL, Burton MJ. Betahistine for Meniere's disease or syndrome. Cochrane Database Syst Rev. 2001;(1):CD001873.
24. Adrion C, Fischer C S, Wagner J, et al. Efficacy and safety of betahistine treatment in patients with Meniere's disease: primary results of a long term, multicentre, double blind, randomised, placebo controlled, dose defining trial (BEMED trial). BMJ. 2016 Jan 21;352:h6816. doi: 10.1136/bmj.h6816.
25. Seyed Tootoonchi SJ, Ghiasi S, Shadara P, et al. Hearing function after betahistine therapyin patients with Meniere’s disease. Braz J Otorhinolaryngol. 2016 Sep- Oct;82(5):500-6. doi: 10.1016/j.bjorl.2015.08.021. Epub 2015 Dec 18.
26. Морозова СВ, Парфенов ВА, Замерград МВ. Бетагистин при вестибулярном головокружении и постмаркетинговая наблюдательная программа VIRTUOSO. Медицинский совет. 2014;(7):34-8. [Morozova SV, Parfenov VA, Zamergrad MV. Betagistin in vestibular vertigo and post-marketing observational program VIRTUOSO. Meditsinskii sovet. 2014;(7):34-8. (In Russ.)].
27. Антоненко ЛМ, Бестужева НВ, Парфенов ВА. Применение препаратов бетагистина при головокружении. Медицинский совет. 2014;(18): 34-40. [Antonenko LM, Bestuzheva NV, Parfenov VA. The use of drugs betahistine in vertigo. Meditsinskii sovet. 2014;(18): 34-40. (In Russ.)].
Review
For citations:
Antonenko L.M., Parfenov V.A. Drug therapy for peripheral vestibular vertigo. Neurology, Neuropsychiatry, Psychosomatics. 2017;9(1):106-110. (In Russ.) https://doi.org/10.14412/2074-2711-2017-1-106-110
Views: 1166
Email this article 